Approved labelTRELSTAR prescribing information for advanced prostate cancer
PopulationAdults covered by the approved TRELSTAR indication
Dose3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks; strengths are not additive or interchangeable by simple summation.
RouteSingle intramuscular injection in either buttock
FrequencyEvery 4, 12, or 24 weeks according to the selected formulation
DurationLong-term use within the approved indication
PreparationLyophilized microsphere suspension supplied with its formulation-specific diluent and MIXJECT transfer system; reconstitute only as directed for the selected 3.75 mg, 11.25 mg, or 22.5 mg product and administer immediately.